1. Roche N, Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54 (13): 1408–13.
2. Buist A, McBurnie M, Vollmer W et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370 (9589): 741–50.
3. Menezes A, Perez-Padilla R, Jardim J et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366 (9500): 1875–81.
4. Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med 2011; 9: 7.
5. World Health Report 2000. Health systems: improving performance. Annex table 3, 2000 World Health Organization. Geneva, Switzerland.
6. Wouters E. COPD: a chronic and overlooked pulmonary disease. Lancet 2007; 370 (9589): 715–6.
7. Mannino D, Buist A. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765–73.
8. Mapel D, Chen J, George D et al. The cost of chronic obstructive pulmonary disease and its effects on managed care. Manag 
Care Interface 2004; 17 (4): 61–6.
9. Lopez A, Murray C. The global burden of disease 1990–2020. Nat Med 1998; 4: 1241–3.
10. Fein A, Fein AM. Management of acute exacerbations in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000; 6 (2): 122–6.
11. Donaldson G, Seemungal T, Bhowmik A et al. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
12. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких 
(пересмотр 2007 г.). Пер. с англ. под ред. А.Г.Чучалина. М.: Атмосфера, 2008.
13. Синопальников А.И., Козлов Р.С., Романовских А.Г., Рачина С.А. Инфекционное обострение ХОБЛ: практические рекомендации по диагностике, лечению и профилактике. Рос. мед. вести. 2006; XI (1): 4–18.
14. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 23–55.
15. Murphy T, Brauer A, Eschberger K et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177 (8): 853–60.
16. Anthonisen N, Manfreda J, Warren C et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
17. Puhan M, Vollenweider D, Latshang T et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007; 8: 30.
18. Siempos I, Dimopoulos G, Korbila I et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 1127–37.
19. Wilson R, Schentag J, Ball P, Mandell I. Comparison of gemifloxacin and claritromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Terap 2002; 24: 639–52.
20. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standart antibiotic treatment in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Chest 2004; 125: 953–64.
21. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Инфекции и антимикроб. терапия. 2005; 1: 20–7.
22. Романовских А.Г., Синопальников А.И. Антибактериальная терапия инфекционного обострения ХОБЛ: какой антибиотик предпочесть? Фарматека. 2009; 20: 86–90.
23. Lode H, Eller J, Linnhoff A. Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 2004; 24: 947–53.

А.И.Синопальников1, А.А.Зайцев2 

1. ГОУ ДПО Российская медицинская академия последипломного образования, Москва 
2. ФБУ Главный военный клинический госпиталь им. академика Н.Н.Бурденко Минобороны РФ, Москва